68 results on '"Grover, Shilpa"'
Search Results
2. S226 Genetic Risk for Colorectal Cancer Is Associated With Earlier Onset and Higher Incidence of Immune Checkpoint Inhibitor Colitis
3. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy
4. Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis
5. Continuing Medical Education Questions: March 2023
6. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course
7. S65 Distinct Imaging Patterns of Immune Checkpoint Inhibitor-Induced Acute Pancreatitis
8. Multiple high-grade and rare immune-related adverse events in a colon cancer patient with genomic and cytokine profiling
9. Su1249: CANCER OUTCOMES IN PATIENTS TREATED WITH BIOLOGICS FOR THE TREATMENT OF STEROID-REFRACTORY IMMUNE CHECKPOINT INHIBITOR COLITIS
10. Su1246: PREDICTORS OF NEED FOR BIOLOGIC THERAPY IN IMMUNE CHECKPOINT INHIBITOR COLITIS
11. Tu1172: CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF IMMUNE CHECKPOINT INHIBITOR GASTRITIS IN PATIENTS WITH CANCER
12. Evaluation and Surveillance Strategies for Patients at Increased Risk of Pancreatic Cancer
13. Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer
14. S109 Pancreatic Insufficiency and Time to Disease Progression Following Immune Checkpoint Inhibitor Pancreatic Injury in Advanced Cancers
15. S194 Prognostic Value of IBD-Associated Genetic Variants in Patients With Immune Checkpoint Inhibitor (ICI) Enteritis/Colitis
16. S1653 Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Pancreatitis
17. S195 Initial Pattern of Colitis Is Associated With Disease Outcomes in Patients With Immune Checkpoint Colitis
18. 236 EFFECT OF CORTICOSTEROID DOSING ON OUTCOMES IN HIGH-GRADE IMMUNE CHECKPOINT INHIBITOR HEPATITIS
19. 235 LIVER BIOPSY IS OF LIMITED UTILITY IN THE DIAGNOSIS AND MANAGEMENT OF IMMUNE CHECKPOINT INHIBITOR HEPATITIS IN CANCER PATIENTS
20. Sa284 ETIOLOGY AND OUTCOMES OF PANCREATIC ENZYME ELEVATIONS WITH THE USE OF IMMUNE CHECKPOINT INHIBITORS IN ADVANCED CANCERS
21. Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors
22. Esophagitis dissecans superficialis with immune checkpoint inhibitor therapy
23. Cover
24. Checkpoint inhibitor induced esophagitis with documented resolution on infliximab
25. Medication‐specific variations in morphological patterns of injury in immune check‐point inhibitor‐associated colitis
26. 481 Impact of COVID-19 on Cancer Patients Receiving Immune Checkpoint Inhibitors
27. High Prevalence of Gastrointestinal Manifestations of COVID-19 Infection in Hospitalized Patients With Cancer
28. S0255 High Prevalence of Gastrointestinal Manifestations of COVID-19 Infection in Hospitalized Patients With Cancer
29. Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis
30. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis
31. Management of immunotherapy colitis: Special considerations in the COVID‐19 era
32. Correction to: Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series
33. Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series
34. Characterizing germline APC and MUTYH variants in Ashkenazi Jews compared to other individuals
35. Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service
36. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis
37. Multidisciplinary team management for high grade immune-related adverse events (irAEs): A single center experience.
38. Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
39. Su1188 ABDOMINAL CT SHOULD NOT BE USED TO SCREEN FOR IMMUNE CHECKPOINT INHIBITOR COLITIS
40. Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis
41. Association of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis.
42. Novel clinical definitions for immune-related adverse events (irAEs): A QI intervention to improve accuracy in irAE diagnosis.
43. Defining real-world criteria for immune-related adverse events (irAEs).
44. High prevalence of IBD-associated genetic variants in patients (pts) with immune checkpoint inhibitor (ICI) enteritis/colitis.
45. Lymphocytic colitis–like pattern of mucosal injury and the challenges in diagnosing cancer immunotherapy‐related toxicity
46. Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management
47. Emblica officinalis Irrigation as an Adjunct to Scaling and Root Planing: A Randomized Controlled Clinical Trial
48. Oncogastroenterology
49. Screening for Pancreatic Cancer in High-risk Populations
50. Effect of Subgingivally Delivered 10% Emblica officinalis Gel as an Adjunct to Scaling and Root Planing in the Treatment of Chronic Periodontitis - A Randomized Placebo-controlled Clinical Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.